Medtronic Initiates Study Evaluating Potential of Combination of Pulmonary Vein Isolation and Renal Denervation for Atrial Fibri

Press releases may be edited for formatting or style | April 30, 2015

About Medtronic
Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is the global leader in medical technology - alleviating pain, restoring health and extending life for millions of people around the world.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Training and education based on your needs

Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money

[1] Kaltenbach B, Franke J, Bertog SC, Steinberg DH, Hofmann I, Sievert H. Renal sympathetic denervation as second line therapy in mild resistant hypertension - a pilot study. Catheter Cardiovasc Interv. 2013 Feb;81(2):335-9.
[2] Pokushalov E, Romanov A, Corbucci G, et al. A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension. J Am Coll Cardiol 2012; 60: 1163-1170.

Contacts:
Wendy Dougherty
Public Relations
+1-763-381-1204

Jeff Warren
Investor Relations
+1-763-505-2696

Back to HCB News



You Must Be Logged In To Post A Comment Sign In If you've already created an account, use your email address and password to sign in using the form below. Login Problems: Click here if you are having login issues. Email address: Password: Forgot your password? Login Problems? View our Legal Notice and Privacy Notice Register Registration is Free and Easy. Enjoy the benefits of The World's Leading New & Used Medical Equipment Marketplace. Register Now!